A compound represented by Formula 1 according to the present disclosure, when used in combination with an anticancer drug, may significantly improve the anticancer effect of the anticancer drug, and may induce the same anticancer effect even when the anticancer drug is used in a significantly smaller amount than the conventionally used amount, thereby reducing the side effects caused by administration of the anticancer drug. Furthermore, the compound represented by Formula 1 makes it possible to effectively prevent, alleviate or treat either anticancer-resistant cancer or cancer which recurs or metastasizes after anticancer drug treatment.

A compound represented by Formula 1 according to the present disclosure, when used in combination with an anticancer drug, may significantly improve the anticancer effect of the anticancer drug, and may induce the same anticancer effect even when the anticancer drug is used in a significantly smaller amount than the conventionally used amount, thereby reducing the side effects caused by administration of the anticancer drug. Furthermore, the compound represented by Formula 1 makes it possible to effectively prevent, alleviate or treat either anticancer-resistant cancer or cancer which recurs or metastasizes after anticancer drug treatment.

A compound represented by Formula 1 according to the present disclosure, when used in combination with an anticancer drug, may significantly improve the anticancer effect of the anticancer drug, and may induce the same anticancer effect even when the anticancer drug is used in a significantly smaller amount than the conventionally used amount, thereby reducing the side effects caused by administration of the anticancer drug. Furthermore, the compound represented by Formula 1 makes it possible to effectively prevent, alleviate or treat either anticancer-resistant cancer or cancer which recurs or metastasizes after anticancer drug treatment.

A compound represented by Formula 1 according to the present disclosure, when used in combination with an anticancer drug, may significantly improve the anticancer effect of the anticancer drug, and may induce the same anticancer effect even when the anticancer drug is used in a significantly smaller amount than the conventionally used amount, thereby reducing the side effects caused by administration of the anticancer drug. Furthermore, the compound represented by Formula 1 makes it possible to effectively prevent, alleviate or treat either anticancer-resistant cancer or cancer which recurs or metastasizes after anticancer drug treatment.

The present disclosure provides methods of treating pancreatic cancer by administering a cationic liposomal formulation. Additional therapeutic agents or therapies may also be included.

The present disclosure provides methods of treating pancreatic cancer by administering a cationic liposomal formulation. Additional therapeutic agents or therapies may also be included.

The present disclosure provides methods of treating pancreatic cancer by administering a cationic liposomal formulation. Additional therapeutic agents or therapies may also be included.

Described herein includes a method of treating a cancer. The method includes selecting a patient responsive to treatment with a tubulin binding agent by determining an expression level of a biomarker panel; and administering the tubulin binding agent to the selected patient. The biomarker can be one or more probesets listed in Tables 1-2 or 4 or the gene expressions identifiable using the probesets listed in Tables 1-2 or 4.

Described herein includes a method of treating a cancer. The method includes selecting a patient responsive to treatment with a tubulin binding agent by determining an expression level of a biomarker panel; and administering the tubulin binding agent to the selected patient. The biomarker can be one or more probesets listed in Tables 1-2 or 4 or the gene expressions identifiable using the probesets listed in Tables 1-2 or 4.

Described herein includes a method of treating a cancer. The method includes selecting a patient responsive to treatment with a tubulin binding agent by determining an expression level of a biomarker panel; and administering the tubulin binding agent to the selected patient. The biomarker can be one or more probesets listed in Tables 1-2 or 4 or the gene expressions identifiable using the probesets listed in Tables 1-2 or 4.